|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine显示文摘The outbreak of Coronavirus Disease 2019(COVID-19)has posed a serious threat to global public health,calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),also known as 2019 novel coronavirus(2019-nCoV).The CoV spike(S)protein plays the most important roles in viral attachment,fusion and entry,and serves as a target for development of antibodies,entry inhibitors and vaccines.Here,we identified the receptor-binding domain(RBD)in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2(ACE2)receptors.SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and,hence,attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells,thus inhibiting their infection to host cells.SARS-CoV RBD-specific antibodies could crossreact with SARS-CoV-2 RBD protein,and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2,suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection. | Wanbo Tai Lei He Xiujuan Zhang Jing Pu Denis Voronin Shibo Jiang Yusen Zhou Lanying Du | 2020 | Cellular & Molecular Immunology2020，17，6： | 35 |
| 2 | A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2显示文摘Dear Editor,The pandemic of coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)highlights the need to develop effective and safe vaccines.Similar to SARS-CoV,SARS-CoV-2 recognizes angiotensin-converting enzyme 2(ACE2)as receptor for host cell entry.1,2 SARS-CoV-2 spike(S)protein consists of S1,including receptor-binding domain(RBD),and S2 subunits.3,4 We previously demonstrated that RBDs of SARS-CoV and MERS-CoV serve as important targets for the development of effective vaccines. | Wanbo Tai Xiujuan Zhang Aleksandra Drelich Juan Shi Jason CHsu Larry Luchsinger Christopher D.Hillyer Chien-Te KTseng Shibo Jiang Lanying Du | 2020 | Cell Research2020，30，10： | 5 |
| 3 | Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses显示文摘Dear Editor,The 2002–2003 global pandemic caused by severe acute respiratory syndrome coronavirus(SARS-CoV)infected around 8,000 people with 10%mortality(http://gffzz36b398b81f8a4a4ch0x6cu6pwkv6n6bw6.ffgz.tsg.suse.edu.cn/csr/sars/en/).The virus has a positivestranded RNA genome that encodes a large polyprotein(1a and 1ab),four structural proteins,including spike(S), | Lei-Ping Zeng Xing-Yi Ge Cheng Peng Wanbo Tai Shibo Jiang Lanying Du Zheng-Li Shi | 2017 | Science China(Life Sciences)2017，60，12： | 4 |
| 4 | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant显示文摘Dear Editor,The COVID-19 pandemic has had a devastating effect on global health,resulting in over 6.2 million deaths worldwide.Continuous emergence of adaptive mutations of SARS-CoV-2 alters its pathogenicity and transmissibility,and renders its resistance to current vaccines and antiviral drugs.1 A new variant named Omicron discovered initially in South Africa has recently been proposed as a variant of concern(VOC)by the World Health Organization,because of its high transmissibility and resistance to current vaccines and therapeutic antibodies.2 Therefore,development of vaccines against prevalent variants including Omicron is urgently needed for COVID-19 prevention. | Wanbo Tai Benjie Chai Shengyong Feng Xinyu Zhuang Jun Ma Mujia Pang Lin Pan Zi Yang Mingyao Tian Gong Cheng | 2022 | Signal Transduction and Targeted Therapy2022，7，7： | 1 |
| 5 | T-cell immunity:a barrier to Omicron immune evasion显示文摘A recent study published in Cell by Naranbhai et al.disclosed that although the extent may vary,T-cell responses induced by infection by or vaccination against the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)are cross-reactive toward the Omicron variant in most individuals,highlighting the role T-cell immunity plays in preventing immune evasion by the Omicron and even future variants. | Fei Yu Wanbo Tai Gong Cheng | 2022 | Signal Transduction and Targeted Therapy2022，7，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员